PortfoliosLab logo
AMRX vs. CORT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AMRX and CORT is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

AMRX vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

0.00%2,000.00%4,000.00%6,000.00%8,000.00%10,000.00%December2025FebruaryMarchAprilMay
52.00%
6,191.07%
AMRX
CORT

Key characteristics

Sharpe Ratio

AMRX:

0.19

CORT:

1.54

Sortino Ratio

AMRX:

0.56

CORT:

4.08

Omega Ratio

AMRX:

1.06

CORT:

1.55

Calmar Ratio

AMRX:

0.08

CORT:

4.12

Martin Ratio

AMRX:

0.70

CORT:

12.00

Ulcer Index

AMRX:

9.77%

CORT:

15.61%

Daily Std Dev

AMRX:

35.97%

CORT:

122.14%

Max Drawdown

AMRX:

-97.52%

CORT:

-94.28%

Current Drawdown

AMRX:

-85.93%

CORT:

-38.31%

Fundamentals

Market Cap

AMRX:

$3.51B

CORT:

$7.72B

EPS

AMRX:

-$0.04

CORT:

$1.23

PS Ratio

AMRX:

1.24

CORT:

11.62

PB Ratio

AMRX:

86.10

CORT:

11.36

Total Revenue (TTM)

AMRX:

$2.83B

CORT:

$685.45M

Gross Profit (TTM)

AMRX:

$1.04B

CORT:

$674.70M

EBITDA (TTM)

AMRX:

$511.54M

CORT:

$111.33M

Returns By Period

In the year-to-date period, AMRX achieves a -8.84% return, which is significantly lower than CORT's 39.83% return. Over the past 10 years, AMRX has underperformed CORT with an annualized return of -16.78%, while CORT has yielded a comparatively higher 29.13% annualized return.


AMRX

YTD

-8.84%

1M

0.14%

6M

-15.06%

1Y

10.91%

5Y*

15.32%

10Y*

-16.78%

CORT

YTD

39.83%

1M

-5.61%

6M

29.93%

1Y

187.83%

5Y*

39.49%

10Y*

29.13%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AMRX vs. CORT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMRX
The Risk-Adjusted Performance Rank of AMRX is 5656
Overall Rank
The Sharpe Ratio Rank of AMRX is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of AMRX is 5454
Sortino Ratio Rank
The Omega Ratio Rank of AMRX is 5050
Omega Ratio Rank
The Calmar Ratio Rank of AMRX is 5656
Calmar Ratio Rank
The Martin Ratio Rank of AMRX is 6161
Martin Ratio Rank

CORT
The Risk-Adjusted Performance Rank of CORT is 9696
Overall Rank
The Sharpe Ratio Rank of CORT is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of CORT is 9898
Sortino Ratio Rank
The Omega Ratio Rank of CORT is 9797
Omega Ratio Rank
The Calmar Ratio Rank of CORT is 9898
Calmar Ratio Rank
The Martin Ratio Rank of CORT is 9696
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AMRX vs. CORT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current AMRX Sharpe Ratio is 0.19, which is lower than the CORT Sharpe Ratio of 1.54. The chart below compares the historical Sharpe Ratios of AMRX and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00December2025FebruaryMarchAprilMay
0.31
1.55
AMRX
CORT

Dividends

AMRX vs. CORT - Dividend Comparison

Neither AMRX nor CORT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AMRX vs. CORT - Drawdown Comparison

The maximum AMRX drawdown since its inception was -97.52%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AMRX and CORT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-85.93%
-38.31%
AMRX
CORT

Volatility

AMRX vs. CORT - Volatility Comparison

The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 14.26%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 17.50%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%December2025FebruaryMarchAprilMay
14.26%
17.50%
AMRX
CORT

Financials

AMRX vs. CORT - Financials Comparison

This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M200.00M300.00M400.00M500.00M600.00M700.00M20212022202320242025
695.42M
157.21M
(AMRX) Total Revenue
(CORT) Total Revenue
Values in USD except per share items

AMRX vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20212022202320242025
36.8%
98.5%
(AMRX) Gross Margin
(CORT) Gross Margin
AMRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a gross profit of 255.89M and revenue of 695.42M. Therefore, the gross margin over that period was 36.8%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a gross profit of 154.81M and revenue of 157.21M. Therefore, the gross margin over that period was 98.5%.

AMRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported an operating income of 100.35M and revenue of 695.42M, resulting in an operating margin of 14.4%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported an operating income of 3.42M and revenue of 157.21M, resulting in an operating margin of 2.2%.

AMRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a net income of 24.62M and revenue of 695.42M, resulting in a net margin of 3.5%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a net income of 20.29M and revenue of 157.21M, resulting in a net margin of 12.9%.